GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Yizhong Pharmaceutical Co 688091.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

36.30

-0.68%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥317.1m

FY2017FY2025

Net income

CN¥64.1m

FY2017FY2025

Free cash flow

−CN¥149.5m

FY2017FY2025

Shareholders' equity

CN¥1.43bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥317.1mCN¥173.5mCN¥360.3mCN¥236.0mCN¥4.1m————
Gross profitCN¥317.1mCN¥160.2mCN¥336.6mCN¥219.0mCN¥3.8m−CN¥7.1m−CN¥6.0m−CN¥5.5m—
Research and developmentCN¥86.4mCN¥37.2mCN¥22.5mCN¥7.9mCN¥13.2mCN¥17.9mCN¥178.7mCN¥13.5mCN¥14.9m
Operating incomeCN¥62.1mCN¥9.5mCN¥195.5mCN¥151.6m−CN¥9.3m−CN¥21.8m−CN¥315.2m−CN¥12.6m−CN¥10.1m
Net incomeCN¥64.1mCN¥7.0mCN¥161.6mCN¥142.9m−CN¥4.0m−CN¥21.8m−CN¥315.2m−CN¥12.6m−CN¥10.1m
Diluted earnings per share0.290.028.160.70-0.03-0.14-1.44-0.06-0.05

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥1.53bnCN¥1.45bnCN¥1.57bnCN¥1.35bnCN¥1.20bnCN¥258.8mCN¥277.6mCN¥229.3mCN¥213.7m
Cash and short-term investments—CN¥666.1mCN¥1.24bnCN¥1.13bnCN¥953.1mCN¥51.1mCN¥130.5mCN¥3.2mCN¥2.7m
Total liabilitiesCN¥96.8mCN¥43.0mCN¥108.5mCN¥35.4mCN¥25.0mCN¥15.3mCN¥12.3mCN¥17.1mCN¥16.2m
DebtCN¥25.0m—CN¥44.0m—CN¥16.8mCN¥3.3m———
Shareholders' equityCN¥1.43bnCN¥1.41bnCN¥1.46bnCN¥1.32bnCN¥1.18bnCN¥243.5mCN¥265.4mCN¥212.2mCN¥197.6m
Shares outstanding220m318m20m205m133m156m220m220m220m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−CN¥19.4mCN¥39.4mCN¥86.6mCN¥110.8m−CN¥48.8m−CN¥20.2m−CN¥23.9m−CN¥10.7m−CN¥11.5m
Capital spending−CN¥130.1m−CN¥80.0m−CN¥8.8m−CN¥35.9m−CN¥3.1m−CN¥5.0m−CN¥47.6m−CN¥3.5m−CN¥1.1m
Free cash flow−CN¥149.5m−CN¥40.6mCN¥77.8mCN¥74.9m−CN¥51.9m−CN¥25.2m−CN¥71.5m−CN¥14.1m−CN¥12.6m
Dividends paid−CN¥73,750−CN¥49.8m−CN¥43.4m−CN¥491,425−CN¥588,864————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥86.7mCN¥79.2mCN¥73.9mCN¥82.8mCN¥89.3mCN¥71.0mCN¥3.9mCN¥47.7m
Gross profitCN¥73.8mCN¥67.5mCN¥114.6mCN¥70.1mCN¥74.5mCN¥57.8m−CN¥219,533CN¥45.1m
Operating incomeCN¥20.5mCN¥12.8mCN¥11.7mCN¥9.2mCN¥24.7mCN¥16.5m−CN¥32.9m−CN¥139,656
Net incomeCN¥24.1mCN¥18.2mCN¥13.5mCN¥12.7mCN¥23.8mCN¥14.2m−CN¥27.7mCN¥161,168
Diluted earnings per share0.110.080.060.060.110.06-0.090.00
Cash from operations———CN¥21.0mCN¥5.0m−CN¥35.0mCN¥18.0mCN¥20.0m
Capital spending−CN¥6.0m−CN¥16.0m−CN¥23.0m−CN¥30.0m−CN¥76.0m—−CN¥27.0m−CN¥35.0m
Free cash flow———−CN¥9.0m−CN¥71.0m—−CN¥9.0m−CN¥15.0m
Total assetsCN¥1.60bnCN¥1.55bnCN¥1.53bnCN¥1.54bnCN¥1.49bnCN¥1.47bnCN¥1.45bnCN¥1.49bn
Cash and short-term investments———CN¥475.1mCN¥543.5mCN¥611.4mCN¥666.1mCN¥654.1m
DebtCN¥25.0mCN¥25.0mCN¥25.0m————CN¥10.9m
Shareholders' equityCN¥1.49bnCN¥1.45bnCN¥1.43bnCN¥1.46bnCN¥1.45bnCN¥1.42bnCN¥1.41bnCN¥1.44bn

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%92.3%93.4%92.8%92.7%—
Operating margin19.6%5.5%54.3%64.2%-227.6%—
Net margin20.2%4.0%44.8%60.5%-98.0%—
Return on equity4.5%0.5%11.0%10.8%-0.3%-9.0%
Return on assets4.2%0.5%10.3%10.5%-0.3%-8.4%
Free cash flow yield1.3%1.0%12.2%1.8%-0.9%-0.2%
Revenue growth82.7%-51.8%52.7%5686.8%——
Earnings growth819.4%-95.7%13.1%-3674.0%-81.7%-93.1%
Current ratio9.17x19.68x13.59x40.17x47.08x5.01x
Debt to equity0.02x—0.03x—0.01x0.01x
Equity ratio93.7%97.0%93.1%97.4%97.9%94.1%
Interest coverage924.43x11.99x607.05x48694.93x-15.76x-1784.09x
R&D as a share of sales27.2%21.4%6.2%3.4%324.7%—
Buybacks as a share of market value31.0%-1506.6%90.3%-54.5%14.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.4%——
Operating income-25.7%——
Net income-23.4%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin97.3%95.0%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings160.9—6.070.1-767.2
Price to sales32.573.22.742.5—

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 17 May 2024.

FY2024FY2023
Paid in the year0.310.231
  • 13-for-10 split · 17 May 2024
  • 11-for-10 split · 20 Apr 2023
  • 1.36-for-1 split · 20 Oct 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.